Anaesthetic considerations in patients with chronic pulmonary disease

Current Opinion in Anaesthesiology

Volumn 16, Issue 3, 2003, Pages 323-330

  Henzler, Dietrich ^a   Rossaint, Rolf ^a   Kuhlen, Ralf ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Anesthesia; Obstructive lung disease; Risk management

Indexed keywords

AMINOPHYLLINE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; HYDROCORTISONE; IPRATROPIUM BROMIDE; KETAMINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MAGNESIUM; METHYLPREDNISOLONE; METHYLXANTHINE; METOPROLOL; MONTELUKAST; OXITROPIUM BROMIDE; OXYGEN; PROPOFOL; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; UNINDEXED DRUG; ZAFIRLUKAST;

ANESTHESIST; ARTIFICIAL VENTILATION; ASTHMA; ASTHMATIC STATE; BLOOD GAS ANALYSIS; BRONCHOSPASM; CHOLECYSTECTOMY; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTINUING EDUCATION; DISEASE EXACERBATION; GENERAL ANESTHESIA; HUMAN; HYPERGLYCEMIA; INTUBATION; LAPAROSCOPY; LUNG FUNCTION; MEDICAL EXPERT; MEDICAL PRACTICE; PATIENT MONITORING; PERIOPERATIVE PERIOD; POSITIVE END EXPIRATORY PRESSURE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; PREMEDICATION; PREVALENCE; PRIORITY JOURNAL; REGIONAL ANESTHESIA; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SPINAL ANESTHESIA; SPIROMETRY; SYMPTOMATOLOGY; TECHNIQUE; THORAX EPIDURAL ANESTHESIA; TREATMENT OUTCOME;

EID: 0038282542     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200306000-00014     Document Type: Review

References (78)

1. Murray CJL, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease. Science 1996; 274:740-743.
2. Warner DO, Warner MA, Offord KP, et al. Airway obstruction and perioperative complications in smokers undergoing abdominal surgery. Anesthesiology 1999; 90:372-379.
3. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999; 340:937-944.
4. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121 (suppl):121S-126S. This is a comprehensive review.
5. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8:1398-1420.
6. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276.
7. Sestini P, Renzoni E, Robinson S, et al. Short-acting beta2 agonists for stable chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library Issue 4. Oxford: Update Software; 2002.
8. Walters EH, Walters JA, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma (Cochrane Review). The Cochrane Library, Issue 4. Oxford: Update Software; 2002.
9. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113:59-65.
10. Lee-Wong M, Dayrit FM, Kohli AR, et al. Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. Chest 2002; 122:1208-1213.
11. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165:1377-1383.
12. Stoloff S, Poinsett-Holmes K, Dorinsky PM. Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management. Pharmacotherapy 2002; 22:212-226.
13. Ram F, Jones P, Castro A, et al. Oral theophylline for chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library, Issue 4. Oxford: Update Software; 2002.
14. Culpitt SV, De Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165:1371-1376.
15. Dempsey OJ, Fowler SJ, Wilson A, et al. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002; 122:151-159. A cross-over study in 24 patients showing the superiority of inhaled corticosteroids over LTRA or theophylline in moderate asthma.
16. Brabson JH, Clifford D, Kerwin E, et al. Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. Am J Med 2002; 113:15-21.
17. Ferreira MB, Santos AS, Pregal AL, et al. Leukotriene receptor antagonists (Montelukast) in the treatment of asthma crisis: preliminary results of a double-blind placebo controlled randomized study. Allerg Immunol (Paris) 2001; 33:315-318.
18. Silverman RA, Osborn H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest 2002; 122:489-497.
19. Noppen M. Magnesium treatment for asthma: where do we stand? Chest 2002; 122:396-397. An editorial on the usefulness of randomized controlled trials and web-informed patients.
20. Travers AH, Rowe BH, Barker S, et al. The effectiveness of IV beta-agonists in treating patients with acute asthma in the emergency department: a meta-analysis. Chest 2002; 122:1200-1207. The only meta-analysis on comparing intravenous versus inhaled therapy, even though contributing studies are up to 30 years old. No benefit could be demonstrated for intravenous treatment.
21. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340:1941-1947.
22. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354:456-460.
23. Nakamura H, Matsuse H, Obase Y, et al. Clinical evaluation of anaphylactic reactions to intravenous corticosteroids in adult asthmatics. Respiration 2002; 69:309-313.
24. Sayiner A, Aytemur ZA, Cirit M, et al. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001; 119:726-730.
25. Stanbrook MB, Goldstein RS. Steroids for acute exacerbations of COPD: how long is enough? Chest 2001; 119:675-676.
26. Wood-Baker R, Walters EH, Gibson P. Oral corticosteroids for acute exarcerbations of chronic obstructive pulmonary disease (Cochrane review). The Cochrane Library, Issue 4. Oxford: Update Software; 2002.
27. Vanpee D, El Khawand C, Rousseau L, et al. Effects of nasal pressure support on ventilation and inspiratory work in normocapnic and hypercapnic patients with stable COPD. Chest 2002; 122:75-83.
28. Keenan SP, Kernerman PD, Cook DJ, et al. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta-analysis. Crit Care Med 1997; 25:1685-1692.
29. International Consensus Conferences in Intensive Care Medicine. Noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001; 163:283-291.
30. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333:817-822.
31. Conti G, Antonelli M, Navalesi P, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med 2002; 28:1701-1707. A prospective randomized study in 49 patients with exacerbated COPD and failed medical therapy. NIV prevented intubation in half of the patients, and reduced ICU stay and mortality. Improved outcome was measurable even after one year.
32. Antonelli M, Conti G, Pelosi P, et al. New treatment of acute hypoxemic respiratory failure: noninvasive pressure support ventilation delivered by helmet - a pilot controlled trial. Crit Care Med 2002; 30:602-608. An interesting report encouraging us to try new treatment modalties.
33. Afessa B, Morales IJ, Scanlon PD, et al. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med 2002; 30:1610-1615.
34. Kress JP, Noth I, Gehlbach BK, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med 2002; 165:1317-1321. A well designed randomized controlled trial showing improved lung function by the use of heliox in a relatively small number of patients.
35. Gerbeaux P, Gainnier M, Boussuges A, et al. Use of heliox in patients with severe exacerbation of chronic obstructive pulmonary disease. Crit Care Med 2001; 29:2322-2324.
36. Gomersall CD, Joynt GM, Freebairn RC, et al. Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Crit Care Med 2002; 30:113-116. A pilot study challenging the traditionally taught restriction of supplemental oxygen by reducing the rate of poor outcome with oxygen therapy, but confirmation has to come from larger trials.
37. 1 with a single administration of cardioselective β-blockers, and none in long-term use. The authors conclude to save the usage of cardioselective β-blockers even in reactive airways disease.
38. Wellstein A, Palm D, Belz GG, et al. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J 1987; 8 (Suppl. M):3-8.
39. Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 346:988-994. A clinical case presentation and comprehensive review of treatment strategies.
40. Aneman A, Eisenhofer G, Fandriks L, et al. Splanchnic circulation and regional sympathetic outflow during peroperative PEEP ventilation in humans. Br J Anaesth 1999; 82:838-842.
41. Bredenberg CE, Paskanik A, Fromm D. Portal hemodynamics in dogs during mechanical ventilation with positive end-expiratory pressure. Surgery 1981; 90:817-822.
42. Pepe PE, Marini JJ. Occult positive end-expiratory pressure in mechanically ventilated patients with airflow obstruction: the auto-PEEP effect. Am Rev Respir Dis 1982; 126:166-170.
43. Koh Y. Ventilatory management of patients with severe asthma. Int Anesthesiol Clin 2001; 39:63-73.
44. Brochard L. Intrinsic (or auto-) PEEP during controlled mechanical ventilation. Intensive Care Med 2002; 28:1376-1378. A brief, but concise explanation of the terms and physiology connected with dynamic hyperinflation.
45. Froese AB, Bryan AC. Effects of anesthesia and paralysis on diaphragmatic mechanics in man. Anesthesiology 1974; 41:242-255.
46. Krayer S, Rehder K, Vettermann J, et al. Position and motion of the human diaphragm during anesthesia-paralysis. Anesthesiology 1989; 70:891-898.
47. Gunnarsson L, Tokics L, Lundquist H, et al. Chronic obstructive pulmonary disease and anaesthesia: formation of atelectasis and gas exchange impairment. Eur Respir J 1991; 4:1106-1116.
48. Kleinman BS, Frey K, VanDrunen M, et al. Motion of the diaphragm in patients with chronic obstructive pulmonary disease while spontaneously breathing versus during positive pressure breathing after anesthesia and neuromuscular blockade. Anesthesiology 2002; 97:298-305. A fluoroscopy study on diaphragmatic movement in 24 patients. Regional diaphragmatic excursion in patients with COPD during spontaneous breathing and controlled ventilation is similar to that in individuals with normal pulmonary function.
49. Yang SC, Yang SP. Effects of inspiratory flow waveforms on lung mechanics, gas exchange, and respiratory metabolism in COPD patients during mechanical ventilation. Chest 2002; 122:2096-2104. A well done clinical study adding another aspect to the ongoing discussion on choosing the right inspiratory flow pattern.
50. Dembinski R, Max M, Bensberg R, et al. Pressure support compared with controlled mechanical ventilation in experimental lung injury. Anesth Analg 2002; 94:1570-1576.
51. Stewart TE, Meade MO, Cook DJ, et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. N Engl J Med 1998; 338:355-361.
52. Guerin C, Lemasson S, La Cara MF, et al. Physiological effects of constant versus decelerating inflation flow in patients with chronic obstructive pulmonary disease under controlled mechanical ventilation. Intensive Care Med 2002; 28:164-169. A crossover study in 10 patients showing the influence of flow rate on respiratory mechanics, but not haemodynamics or gas exchange.
53. Kroenke K, Lawrence VA, Theroux JF, et al. Posoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest 1993; 1445-1451.
54. Mutlu GM, Factor P, Schwartz DE, et al. Severe status asthmaticus: management with permissive hypercapnia and inhalation anesthesia. Crit Care Med 2002; 30:477-480.
55. Scalfaro P, Sly PD, Sims C, et al. Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children. Anesth Analg 2001; 93:898-902.
56. Groeben H, Schlicht M, Stieglitz S, et al. Both local anesthetics and salbutamol pretreatment affect reflex bronchoconstriction in volunteers with asthma undergoing awake fiberoptic intubation. Anesthesiology 2002; 97:1445-1450.
57. Conti G, De Cosmo G, Bocci MG, et al. Alfentanil does not increase resistance of the respiratory system in ASA I patients ventilated mechanically during general anesthesia. Can J Anaesth 2002; 49:718-723.
58. Nishiyama T, Hanaoka K. Propofol-induced bronchoconstriction: two case reports. Anesth Analg 2001; 93:645-646.
59. Hepner DL. Propofol-induced bronchoconstriction: asthma or allergy? Anesth Analg 2002; 94:1045.
60. Natalini G, Franceschetti ME, Pletti C, et al. Impact of laryngeal mask airway and tracheal tube on pulmonary function during the early postoperative period. Acta Anaesthesiol Scand 2002; 46:525-528.
61. Aye T, Milne B. Ketamine anesthesia for pericardial window in a patient with pericardial tamponade and severe COPD. Can J Anaesth 2002; 49:283-286.
62. Vanek T, Straka Z, Brucek P, et al. Thoracic epidural anaesthesia for off-pump coronary artery bypass without intubation. Eur J Cardiothorac Surg 2001; 20:858-860. A report on a series of 10 patients, warranting good nerves of the surgeon and anaesthetist.
63. Flores JA, Nishibe T, Koyama M, et al. Combined spinal and epidural anesthesia for abdominal aortic aneurysm surgery in patients with severe chronic pulmonary obstructive disease. Int Angiol 2002; 21:218-221.
64. Visser WA, Liem TH, Brouwer RM. High thoracic epidural anesthesia for coronary artery bypass graft surgery in a patient with severe obstructive lung disease. J Cardiothorac Vasc Anesth 2001; 15:758-760. A detailed description of one case, which is interesting in terms of how-to-do-it, why-to-do-it and when-to-do-it.
65. Freund FG, Bonica JJ, Ward RJ. Ventilatory reserve and level of motor block during high spinal and epidural anesthesia. Anesthesiology 1967; 28:834-837.
66. Takasaki M, Takahashi T. Respiratory function during cervical and thoracic analgesia in patients with normal lungs. Br J Anaesth 1980; 52:1271-1275.
67. 1 in both groups, which was less pronounced than changing the position from sitting to supine.
68. Gruber EM, Tschernko EM, Kritzinger M, et al. The effects of thoracic epidural analgesia with bupivacaine 0.25% on ventilatory mechanics in patients with severe chronic obstructive pulmonary disease. Anesth Analg 2001; 92:1015-1019.
69. Zollinger A, Hofer C, Pasch T. Preoperative pulmonary evaluation: facts and myths. Curr Opin Anaesthesiol 2002; 14:59-63.
70. Fisher BW, Majumdar SR, McAlister FA. Predicting pulmonary complications after nonthoracic surgery: a systematic review of blinded studies. Am J Med 2002; 112:219-225.
71. Arozullah AM, Daley J, Henderson WG, et al. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg 2000; 232:242-253.
72. Arozullah AM, Khuri SF, Henderson WG, et al. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Ann Emerg Mad 2001; 135:847-857.
73. 1 and hypercarbia were strong predictors of outcome, but the type of surgery and anaesthesia were not.
74. Hasukic S, Mesic D, Dizdarevic E, et al. Pulmonary function after laparoscopic and open cholecystectomy. Surg Endosc 2002; 16:163-165.
75. Neudecker J, Sauedand S, Neugebauer E, et al. The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery. Surg Endosc 2002; 16:1121-1143.
76. Gramatica Jr L, Brasesco OE, Mercado LA, et al. Laparoscopic cholecystectomy performed under regional anesthesia in patients with chronic obstructive pulmonary disease. Surg Endosc 2002; 16:472-475.
77. Andersson L, Lagerstrand L, Thorne A, et al. Effect of CO(2) pneumoperitoneum on ventilation-perfusion relationships during laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2002; 46:552-560.
78. American Thoracic Society. Guidelines for the six-minute walk test. Am J Respir Crit Care Mad 2002; 166:111-117.